ESC Professional Premium Access

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

Topic: Renal Failure and Cardiovascular Disease

Congress Session

About the speaker

Doctor Ajay Singh

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
0 follower

5 more presentations in this session

Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

Speaker: Doctor K. Mahaffey (Stanford, US)

Thumbnail

Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial

Speaker: Ms A. Pettersson Meyer (DK)

Thumbnail

CAD in kidney transplant recipients: a real-world assessment pre-ISCHEMIA-CKD

Speaker: Doctor B. Rocha (Lisbon, PT)

Thumbnail

Epigenetic regulation of miR-181c-5p in a cardiorenal mouse model with co-occurring thrombotic microangiopathy

Speaker: Ms J. Boen (Antwerp, BE)

Thumbnail

The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients

Speaker: Associate Professor W. Wongcharoen (Chiang Mai, TH)

Thumbnail

Access the full session

Renal failure and cardiovascular disease 2

Speakers: Doctor A. Singh, Doctor K. Mahaffey, Ms A. Pettersson Meyer, Doctor B. Rocha, Ms J. Boen...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk